Consumer Spin-Off Finally Achieved, GSK Will Weigh More M&A
Could Have £12bn To Spend On M&A
GSK is entering a new era, and CEO Emma Walmsley looks likely to use new finances for more targeted M&A.
You may also be interested in...
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.